Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H16N2O |
Molecular Weight | 204.2682 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC1=CNC2=C1C=C(O)C=C2
InChI
InChIKey=VTTONGPRPXSUTJ-UHFFFAOYSA-N
InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3
Molecular Formula | C12H16N2O |
Molecular Weight | 204.2682 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24650558
Curator's Comment: referenced study was conducted in rat
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q64264 Gene ID: 15550.0 Gene Symbol: Htr1a Target Organism: Mus musculus (Mouse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25446678 |
|||
Target ID: P35363 Gene ID: 15558.0 Gene Symbol: Htr2a Target Organism: Mus musculus (Mouse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25446678 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25446678
Curator's Comment: referenced study was conducted on mice.
Age-matched wild-type FVB/N and Tg-CYP2D6 mice were given an intraperitoneal dose of either harmaline 90, 2, 5, or 15 mg/kg) or bufotenine (0, 2, 10 0r 20 mg/kg). Wild-type and Tg-CYP2D6 mice exhibited hyperthermia with high doses of bufotenine ( 10 and 20 mg/kg).
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2706543
To determine if serotonin is involved in associative conditioning-produced changes of Type B photo-receptors, isolated nervous systems were exposed to a conditioning procedure in the absence or presence of drugs that alter normal serotonergic neurotransmission. Nervous systems were dissected, mounted and treated with protease before washing with artificial seawater (ASW), or ASW containing 100 microM bufotenine. When treated bufotenine clearly reduced the pairing specific cumulative depolarization and changes in input resistance. Treatment involving bufotenine suggests that serotonin modulates Type B photoreceptor excitability during associative conditioning.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:48:40 GMT 2023
by
admin
on
Fri Dec 15 18:48:40 GMT 2023
|
Record UNII |
0A31347TZK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
7433
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
||
|
WIKIPEDIA |
TiHKAL
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
89593
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
DB01445
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
10257
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
BUFOTENIN
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
0A31347TZK
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
DTXSID0048894
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
m2753
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
207-667-9
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
3210
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
487-93-4
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
PARENT -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|